Fig. 1: Flow of patients in the study.
From: Utility of flow cytometry screening before MRD testing in multiple myeloma
We initially identified all patients with a plasma cell (PC) disorder who underwent plasma cell proliferation (PCPRO) testing. Treated patients with multiple myeloma (MM) and PC leukemia (PCL) who were considered measurable residual disease (MRD) testing-eligible were identified and the proportion of patients in whom MRD testing was avoided by a positive PCPRO was calculated. BMPC bone marrow plasma cell, EM extramedullary, MGUS monoclonal gammopathy of undetermined significance, SMM smoldering multiple myeloma.
